Alexander I. Spira

Also affiliated with Virginia Cancer Specialists

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial”.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00541-1

N/A

5.0DataRank · unranked

426 citations

Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss +10 more

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00103-4

N/A

2.5DataRank · unranked

86 citations

Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies +13 more

Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9544

N/A

0.269DataRank · unranked

5 citations

Ari M. Vanderwalde, Hirva Mamdani, Luis E. Raez, Yasmine Baca, Joanne Xiu +14 more

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Cancer Research(2025)10.1158/0008-5472.can-25-0998

N/A

0.241DataRank · unranked

4 citations

Soumyadip Sahu, Minjie Zhang, Ayushi S. Patel, Ke Geng, Reshmee Bhattacharya +47 more

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0795

N/A

0DataRank · unranked

23 citations

Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao +10 more

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.018

N/A

0DataRank · unranked

5 citations

Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Philippe A. Cassier +20 more